Tamoxifen, MP Biomedicals

Description

Tamoxifen, White Powder

• It has been used to facilitate the recombination of ect2flox allele in mouse organs.
• It has also been used to study its effect on lipopolysaccharide (LPS)-induced microglial activation.
• Protein kinase C inhibitor (IC50 = 50-200μM depending on assay conditions in MCF-7 cells or IC50 = 100μM in rat brain).
• It is a prodrug that is metabolized to active metabolites 4-hydroxytamoxifen (4-OHT) and endoxifen by cytochrome P450 isoforms CYP2D6 and CYP3A4.

Specifications

• Melting Point: 96°C to 100°C
• Color: White
• Loss on Drying: 0.0021
• Refractive Index: KR5919600
• Quantity: 5 g
• Synonym: [Z]-1-[p-Dimethylaminoethoxyphenyl]-1,2-diphenyl-1-butene, (Z)-2-[4-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethanamine, ICI 47699, trans-Tamoxifen
• Solubility Information: Practically insoluble in water (< 0.01% at 20°C); soluble in methanol, ethanol, 2-propanol, propyleneglycol, chloroform (50mg/mL - clear, colorless to faint yellow solution) or DMSO
• IUPAC Name: (2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}ethyl)dimethylamine
• Physical Form: Powder
• Assay: 0.9935

Safety and Handling

Product Identifier

• Tamoxifen, Free Base

Signal Word

• Danger

Hazard Category

• Carcinogenicity Category 1A
• Reproductive toxicity Category 1A

Hazard Statement

• H350-May cause cancer.
• H360-May damage fertility or the unborn child.

Precautionary Statement

• P101-If medical advice is needed, have product container or label at hand.
• P102-Keep out of reach of children.
• P103-Read label before use.
• P263-Avoid contact during pregnancy/while nursing.
• P308+P313-IF exposed or concerned: Get medical advice/attention.
• P405-Store locked up.
• P501b-Dispose of contents/container in accordance with local/regional/national/international regulations.

Supplemental information

• MIXTURE LIST-Contains : tamoxifen free base